PositiveID Corp., a developer of medical technologies for diabetes management, today announced that preliminary results from its biotransport research study with the Diabetes Research Institute (DRI) at the University of Miami demonstrate positive data for the company’s GlucoChip ™.
PositiveID’s GlucoChip is a glucose-sensing implantable microchip, currently under development with RECEPTORS LLC, for individuals with diabetes. The company reports that preliminary results demonstrate that the membrane materials to be used with GlucoChip allow for successful movement of glucose from body fluids.
“These first studies were successfully completed with the demonstration that a glucose tracer readily enters the device from surrounding body fluids. We are currently implementing the next phase of these studies, which will focus in more detail on both the kinetics of transport, which will determine how quickly the device will be able to respond to changes in glucose levels in the body, and on the long-term biocompatibility of the membrane,” Robert E. Carlson, Ph.D., RECEPTORS president and chief scientific officer stated in the press release.
PositiveID chairman and CEO William J. Caragol said by achieving the positive results, the company is on-track to overcoming “significant” development challenges.
“We believe the preliminary results from our research study at the DRI are not only positive but also promising as we proceed with our development. By achieving early confirmation that the membrane materials we will use with GlucoChip allow for movement of glucose from fluids in the body into the glucose-sensing device, we have begun to eliminate one of the significant hurdles of this potentially ground-breaking development project,” Caragol stated.
PositiveID and partner RECEPTORS LLC have completed prototype development of a stable and reproducible, closed-cycle continuous glucose-sensing system. Should they achieve continued positive results from the biocompatibility and biotransport, PositiveID will be on-track to complete development of GlucoChip.
For more information visit www.PositiveIDCorp.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
